Shanghai Composite Index Rises 2.23% This Quarter to 3041.17 — Data Talk
The Shanghai Composite Index is up 66.23 points or 2.23% this quarter to 3041.17
--Largest one-quarter point and percentage gain since the 1st quarter 2023
--Snaps a three-quarter losing streak
--This month it is up 26.00 points or 0.86%
--Up for two consecutive months
--Up 252.62 points or 9.06% over the last two months
--Largest two-month point and percentage gain since June 2022
--This week it is down 6.87 points or 0.23%
--Largest one-week point and percentage decline since the week ending Feb. 2, 2024
--Down for two consecutive weeks
--Down 13.47 points or 0.44% over the last two weeks
--Largest two-week point and percentage decline since the week ending Feb. 8, 2024
--Today it is up 30.50 points or 1.01%
--Largest one-day point and percentage gain since Thursday, Feb. 29, 2024
--Up for two consecutive trading days
--Up 48.03 points or 1.60% over the last two trading days
--Largest two-day point and percentage gain since Friday, March 1, 2024
--Up three of the past four trading days
--Off 50.08% from its record close of 6092.06 hit Tuesday, Oct. 16, 2007
--Highest closing value since Friday, March 22, 2024
--Off 10.42% from its 52-week high of 3395.00 hit Monday, May 8, 2023
--Up 12.54% from its 52-week low of 2702.19 hit Monday, Feb. 5, 2024
--Down 7.08% from 52 weeks ago
--Off 1.42% from its 2024 closing high of 3084.93 hit Monday, March 18, 2024
--Up 12.54% from its 2024 closing low of 2702.19 hit Monday, Feb. 5, 2024
--Year-to-date it is up 66.23 points or 2.23%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 29, 2024 09:04 ET (13:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth